{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:14:52Z","timestamp":1758046492518,"version":"3.44.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.pharma.2022.03.004","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T12:09:42Z","timestamp":1650629382000},"page":"932-942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pr\u00e9valence des Effets Ind\u00e9sirables des Inhibiteurs de Tyrosine Kinase Utilis\u00e9s dans le Traitement de la Leuc\u00e9mie My\u00e9lo\u00efde Chronique au CHU de Sidi Bel-Abb\u00e8s"],"prefix":"10.1016","volume":"80","author":[{"given":"D.","family":"Matmour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Si-Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.C.","family":"Benmehimda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Beloufa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Belfrak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Mahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Merad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Toumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Benlazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2022.03.004_bib0005","first-page":"2","article-title":"Leuc\u00e9mie My\u00e9lo\u00efde Chronique: \u00e9pid\u00e9miologie, biologie et r\u00e9sultats th\u00e9rapeutiques","volume":"13","author":"Djouadi-Lahlou","year":"2017","journal-title":"Revue Alg\u00e9rienne d\u2019H\u00e9matologie"},{"key":"10.1016\/j.pharma.2022.03.004_bib0010","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood.V86.6.2371.bloodjournal8662371","article-title":"Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression","volume":"86","author":"Gaiger","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2022.03.004_bib0015","first-page":"3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"10","author":"Michael","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2022.03.004_bib0020","first-page":"497","article-title":"Strat\u00e9gies th\u00e9rapeutiques et recommandations pour la prise en charge des patients atteints de leuc\u00e9mie my\u00e9lo\u00efde chronique","volume":"9","author":"Bories","year":"2003","journal-title":"H\u00e9matologie"},{"key":"10.1016\/j.pharma.2022.03.004_bib0025","first-page":"1451","article-title":"Chronic myeloid leukemia - advances in biology and new approaches to treatment","volume":"15","author":"John","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharma.2022.03.004_bib0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminhematol.2006.12.003","article-title":"New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance","volume":"44","author":"Jabbour","year":"2007","journal-title":"Semin Hematol"},{"issue":"5","key":"10.1016\/j.pharma.2022.03.004_bib0035","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10\u00a0years data from the randomized CML study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.pharma.2022.03.004_bib0040","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","article-title":"Long-term outcome of CML patients treated frontline with imatinib","volume":"29","author":"Castagnetti","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.pharma.2022.03.004_bib0045","first-page":"428","article-title":"Novel agents in CML therapy: tyrosine kinase inhibitors and beyond","author":"Junia","year":"2008","journal-title":"Hematology"},{"key":"10.1016\/j.pharma.2022.03.004_bib0050","first-page":"863","article-title":"Le traitement de la leuc\u00e9mie my\u00e9lo\u00efde chronique en 2007","volume":"94","author":"Labussi\u00e8re","year":"2007","journal-title":"Bull Cancer"},{"key":"10.1016\/j.pharma.2022.03.004_bib0055","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0248-8663(01)00441-6","article-title":"Leuc\u00e9mie my\u00e9lo\u00efde chronique et inhibiteurs de tyrosine kinase","volume":"22","author":"Mahon","year":"2001","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.pharma.2022.03.004_bib0060","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00277-015-2318-y","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia","author":"Rea","year":"2015","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.pharma.2022.03.004_bib0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/2040620713510481","article-title":"Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview","volume":"5","author":"Shen","year":"2014","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.pharma.2022.03.004_bib0070","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series","volume":"176","author":"Bergeron","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharma.2022.03.004_bib0075","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"PACE Investigators. A phase 2\u00a0trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2022.03.004_bib0080","unstructured":"Agence Nationale de S\u00e9curit\u00e9 des M\u00e9dicaments. R\u00e9sum\u00e9 des caract\u00e9ristiques du produit (RCP) de L\u2019IMATINIB RANBAXY\u00ae. Mis \u00e0 jour le: 10\u00a0Octobre 2016. Disponible sur: http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0286655.htm. [Consult\u00e9 le 11\u00a0Janvier 2021]."},{"key":"10.1016\/j.pharma.2022.03.004_bib0085","unstructured":"Agence Nationale de S\u00e9curit\u00e9 des M\u00e9dicaments. R\u00e9sum\u00e9 des caract\u00e9ristiques du produit (RCP) du DASATINIB SPRYCEL\u00ae. Mis \u00e0 jour le: 10 Octobre 2017. Disponible sur: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sprycel-epar-product-information_fr.pdf. [Consult\u00e9 le 12 Janvier 2021]."},{"key":"10.1016\/j.pharma.2022.03.004_bib0090","unstructured":"Agence Nationale de S\u00e9curit\u00e9 des M\u00e9dicaments. R\u00e9sum\u00e9 des caract\u00e9ristiques du produit (RCP) du NILOTINIB TASIGNA\u00ae. Mis \u00e0 jour le: 22 D\u00e9cembre 2016. Disponible sur: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tasigna-epar-product-information_fr.pdf. [Consult\u00e9 le 11 Janvier 2021]."},{"key":"10.1016\/j.pharma.2022.03.004_bib0095","series-title":"International drug monitoring: the role of national centres. report of WHO meeting","first-page":"498","author":"Organisation mondiale de la sant\u00e9.","year":"2012"},{"issue":"10","key":"10.1016\/j.pharma.2022.03.004_bib0100","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/0003-4819-140-10-200405180-00009","article-title":"Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting","volume":"140","author":"Nebeker","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharma.2022.03.004_bib0105","unstructured":"Statistical Package for the Social Sciences (SPSS) version 20. Disponible sur: https:\/\/spss-64\u00a0bits.fr.softonic.com\/. [Consult\u00e9 le 11\u00a0mars 2021]."},{"year":"2016","series-title":"Caract\u00e9risation \u00e9pid\u00e9mio-g\u00e9n\u00e9tique de la population de Tlemcen par le cancer de leuc\u00e9mie chronique. [Th\u00e8se]","author":"Meftahi","key":"10.1016\/j.pharma.2022.03.004_bib0110"},{"year":"2016","series-title":"Leuc\u00e9mie my\u00e9lo\u00efde chronique chez l\u2019adulte: \u00e9tude r\u00e9trospective sur 69\u00a0cas au CHU B\u00e9jaia. [Th\u00e8se]","author":"Messaoudi","key":"10.1016\/j.pharma.2022.03.004_bib0115"},{"key":"10.1016\/j.pharma.2022.03.004_bib0120","article-title":"Prise en charge de la LMC, exp\u00e9rience du service d\u2019h\u00e9matologie de L\u2019 EPH Bordj Bouariridj","author":"Lakehal","year":"2019","journal-title":"Revue alg\u00e9rienne d\u2019h\u00e9matologie"},{"issue":"3","key":"10.1016\/j.pharma.2022.03.004_bib0125","first-page":"189","article-title":"Inhibiteurs de la tyrosine kinase dans le traitement de la leuc\u00e9mie my\u00e9lo\u00efde chronique: exp\u00e9rience du Niger","volume":"16","author":"Malam-Abdou","year":"2015","journal-title":"Health Sci Dis"},{"key":"10.1016\/j.pharma.2022.03.004_bib0130","unstructured":"Loum\u00e9 L. Sept questions sur la leuc\u00e9mie my\u00e9lo\u00efde chronique: sant\u00e9, sciences et avenir. 22\u00a0Septembre 2014. Disponible sur: https:\/\/www.sciencesetavenir.fr\/sante\/7-questions-sur-la-leucemie-myeloide-chronique_27872. [Consult\u00e9 le 10\u00a0Juillet 2021]."},{"year":"2015","series-title":"\u00c9tude de l\u2019association entre les polymorphismes g\u00e9n\u00e9tiques CE77T des m\u00e9thyl\u00e8net\u00e9trahydrofolate r\u00e9ductase (MTHFR) et risque de leuc\u00e9mie my\u00e9lo\u00efde chronique: \u00e0 propos de cas d\u2019une population alg\u00e9rienne. [Th\u00e8se]","author":"Mohammedi","key":"10.1016\/j.pharma.2022.03.004_bib0135"},{"key":"10.1016\/j.pharma.2022.03.004_bib0140","article-title":"Suivi mol\u00e9culaire de la leuc\u00e9mie my\u00e9lo\u00efde chronique par RT-PCR quantitative: r\u00e9sultats \u00e0 18\u00a0mois","author":"Si-Ali","year":"2016","journal-title":"Revue alg\u00e9rienne d\u2019h\u00e9matologie"},{"key":"10.1016\/j.pharma.2022.03.004_bib0145","unstructured":"The National Comprehensive Cancer Network. First-line treatment for chronic phase CML. 2018. Disponible sur: https:\/\/www.nccn.org\/. [Consult\u00e9 le 10\u00a0Juillet 2021]."},{"key":"10.1016\/j.pharma.2022.03.004_bib0150","unstructured":"The National Comprehensive Cancer Network. 2015. Disponible sur: https:\/\/www. leukemia-net.org\/home\/. [Consult\u00e9 le 10\u00a0Juillet 2021]."},{"issue":"1","key":"10.1016\/j.pharma.2022.03.004_bib0155","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/leu.2009.193","article-title":"Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history","volume":"24","author":"Jabbour","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.pharma.2022.03.004_bib0160","unstructured":"CML Advocates Network. Recommandations pour le traitement des personnes vivants avec la LMC; 2020:2-14. Disponible sur: https:\/\/www.cmladvocates.net\/download\/public-files\/publications-of-cml-advocates-network\/eln-recommendations-2020\/1061-eln-recommenda-tions-for-treting-cml-2020-patient-friendly-summary-french\/file. [Consult\u00e9 le 10 Juillet 2021]."},{"issue":"24","key":"10.1016\/j.pharma.2022.03.004_bib0165","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2022.03.004_bib0170","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus Imatinib in newly diagnosed chronic phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.pharma.2022.03.004_bib0175","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharma.2022.03.004_bib0180","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib-resistance or intolerance: 24\u00a0months follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pharma.2022.03.004_bib0185","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3109\/10428194.2011.627480","volume":"53","author":"Nicolini","year":"2012","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.pharma.2022.03.004_bib0190","article-title":"Profil de tol\u00e9rance des antityrosines kinases dans le traitement de la leuc\u00e9mie my\u00e9lo\u00efde chronique","author":"Bouchakor","year":"2016","journal-title":"Revue alg\u00e9rienne d\u2019h\u00e9matologie"},{"issue":"6","key":"10.1016\/j.pharma.2022.03.004_bib0195","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Andreas","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2022.03.004_bib0200","unstructured":"Cony-Makhoul P, Annecy Genevois CH. Leuc\u00e9mie my\u00e9lo\u00efde chronique et inhibiteurs de tyrosine kinase: Mieux comprendre et suivre mon traitement. Pact-Onco. 2019:1-27. Disponible sur: https:\/\/www.pactonco.fr\/sites\/default\/files\/remis_surveillancepatientsweb 00230.pdf. [Consult\u00e9 le 06\u00a0F\u00e9vrier 2021]."}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922000359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922000359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:36:48Z","timestamp":1757720208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450922000359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0003450922000359"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2022.03.004","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pr\u00e9valence des Effets Ind\u00e9sirables des Inhibiteurs de Tyrosine Kinase Utilis\u00e9s dans le Traitement de la Leuc\u00e9mie My\u00e9lo\u00efde Chronique au CHU de Sidi Bel-Abb\u00e8s","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2022.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}